BridgeBio Pharma, Inc. — Director's Dealing 2020

May 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-05-19

Reporting Person: Sinha Uma (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-19	Common Stock	A	1523	$0.00	Acquired	15523	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-19	Stock Option (Right to Buy)	$1.25	A	5366	Acquired	2027-11-15	Common Stock (5366)	Direct
2020-05-19	Stock Option (Right to Buy)	$0.16	A	49361	Acquired	2029-05-23	Common Stock (49361)	Direct
2020-05-19	Stock Option (Right to Buy)	$0.34	A	49765	Acquired	2029-07-14	Common Stock (49765)	Direct
2020-05-19	Stock Option (Right to Buy)	$3.35	A	3022	Acquired	2029-09-30	Common Stock (3022)	Direct

Footnotes

F1: The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a "Subsidiary" and collectively, the "Subsidiaries").

F2: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.

F3: 24,930 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,558 shares shall vest and become exercisable on June 1, 2020, and 22,873 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F4: 25,134 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,571 shares shall vest and become exercisable on June 1, 2020, and 23,060 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.